Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 after gastrectomy: a population-based cohort study using a nationwide claims database
Abstract Although both capecitabine plus oxaliplatin (CAPOX) and S-1 are accepted as adjuvant chemotherapy following gastrectomy for gastric cancer, the better option between the two is still controversial. We conducted a retrospective nationwide cohort study using data from the National Health Insu...
Main Authors: | Chi Hoon Maeng, Hoseob Kim, Mina Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-44117-3 |
Similar Items
-
Time interval between surgery and adjuvant chemotherapy in patients with gastric cancer after gastrectomy: a population-based cohort study using a nationwide claim database
by: Chi Hoon Maeng, et al.
Published: (2024-03-01) -
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
by: Schouten Sander B, et al.
Published: (2010-10-01) -
Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis
by: Sang-Ho Jeong, et al.
Published: (2022-08-01) -
S-1 plus oxaloplatin (S-1OX) versus capecitabine plus oxaloplatin (CAPOX) for advanced gastric cancer: A systematic review and meta-analysis
by: S.M.Zeeshan Qadar, et al.
Published: (2024-01-01) -
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022-07-01)